Literature DB >> 24964

Studies on antituberculotic action of some phenothiazine derivatives in vitro.

J Molnár, I Béládi, I Földes.   

Abstract

Five phenothiazine derivatives (chlorpromazine, levomepromazine, diethazine, promethazine and chlorpromazine) sulphoxyde were tested for antimycobacterial activity. The growth of Mycobacterium tuberculosis, M. bovis and M. butyricum was inhibited by chlorpromazine practically at identical concentrations. The minimum inhibitory concentrations for M. tuberculosis were: chlorpromazine and levomepromazine, 10 microgram/ml; diethazine and promethazine 20 microgram/ml, whilst chlorpromazine sulphoxyde was ineffective even at a concentration of 100 microgram/ml. Chlorpromazine and promethazine exerted a measurable bactericidal activity on M. tuberculosis at 50 microgram/ml; total destruction of the organism and loss of acid fastness in part of the cells were shown at 300 microgram/ml. Preliminary studies, in mouse experiments phenothiazine derivatives were ineffective.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 24964

Source DB:  PubMed          Journal:  Zentralbl Bakteriol Orig A        ISSN: 0300-9688


  9 in total

1.  Inhibitors of type II NADH:menaquinone oxidoreductase represent a class of antitubercular drugs.

Authors:  Edward A Weinstein; Takahiro Yano; Lin-Sheng Li; David Avarbock; Andrew Avarbock; Douglas Helm; Andrew A McColm; Ken Duncan; John T Lonsdale; Harvey Rubin
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-14       Impact factor: 11.205

2.  Clinical concentrations of thioridazine kill intracellular multidrug-resistant Mycobacterium tuberculosis.

Authors:  Diane Ordway; Miguel Viveiros; Clara Leandro; Rosário Bettencourt; Josefina Almeida; Marta Martins; Jette E Kristiansen; Joseph Molnar; Leonard Amaral
Journal:  Antimicrob Agents Chemother       Date:  2003-03       Impact factor: 5.191

3.  Thioridazine pharmacokinetic-pharmacodynamic parameters "Wobble" during treatment of tuberculosis: a theoretical basis for shorter-duration curative monotherapy with congeners.

Authors:  Sandirai Musuka; Shashikant Srivastava; Chandima Wasana Siyambalapitiyage Dona; Claudia Meek; Richard Leff; Jotam Pasipanodya; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2013-09-16       Impact factor: 5.191

Review 4.  Thioridazine: A Non-Antibiotic Drug Highly Effective, in Combination with First Line Anti-Tuberculosis Drugs, against Any Form of Antibiotic Resistance of Mycobacterium tuberculosis Due to Its Multi-Mechanisms of Action.

Authors:  Leonard Amaral; Miguel Viveiros
Journal:  Antibiotics (Basel)       Date:  2017-01-14

Review 5.  Psychotropics and the Microbiome: a Chamber of Secrets….

Authors:  Sofia Cussotto; Gerard Clarke; Timothy G Dinan; John F Cryan
Journal:  Psychopharmacology (Berl)       Date:  2019-02-26       Impact factor: 4.530

6.  2-aminoimidazoles collapse mycobacterial proton motive force and block the electron transport chain.

Authors:  Albert Byungyun Jeon; David F Ackart; Wei Li; Mary Jackson; Roberta J Melander; Christian Melander; Robert B Abramovitch; Adam J Chicco; Randall J Basaraba; Andrés Obregón-Henao
Journal:  Sci Rep       Date:  2019-02-06       Impact factor: 4.379

Review 7.  A Double-Edged Sword: Thioxanthenes Act on Both the Mind and the Microbiome.

Authors:  Marianne Ø Poulsen; Sujata G Dastidar; Debalina Sinha Roy; Shauroseni Palchoudhuri; Jette Elisabeth H Kristiansen; Stephen J Fey
Journal:  Molecules       Date:  2021-12-29       Impact factor: 4.411

8.  Why and How the Old Neuroleptic Thioridazine Cures the XDR-TB Patient.

Authors:  Leonard Amaral; Joseph Molnar
Journal:  Pharmaceuticals (Basel)       Date:  2012-09-17

9.  Treatment with high-dose antidepressants severely exacerbates the pathological outcome of experimental Escherichia coli infections in poultry.

Authors:  Sofie Kromann; Egle Kudirkiene; Lili Li; Ida Thoefner; Elisabeth Daldorph; Jens Peter Christensen; Hecheng Meng; Rikke Heidemann Olsen
Journal:  PLoS One       Date:  2017-10-11       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.